Patents by Inventor Brian T. Frederick
Brian T. Frederick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10030061Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.Type: GrantFiled: November 30, 2017Date of Patent: July 24, 2018Assignee: Protagonist Therapeutics, Inc.Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
-
Publication number: 20180100004Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.Type: ApplicationFiled: September 29, 2017Publication date: April 12, 2018Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
-
Publication number: 20180086811Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.Type: ApplicationFiled: November 30, 2017Publication date: March 29, 2018Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
-
Patent number: 9822157Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.Type: GrantFiled: March 17, 2014Date of Patent: November 21, 2017Assignee: Protagonist Therapeutics, Inc.Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
-
Publication number: 20160222076Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.Type: ApplicationFiled: March 17, 2014Publication date: August 4, 2016Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
-
Publication number: 20130012685Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: July 3, 2012Publication date: January 10, 2013Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
-
Publication number: 20120165275Abstract: Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.Type: ApplicationFiled: December 21, 2011Publication date: June 28, 2012Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
-
Publication number: 20120157660Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: August 18, 2010Publication date: June 21, 2012Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
-
Patent number: 8106154Abstract: Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.Type: GrantFiled: January 30, 2008Date of Patent: January 31, 2012Assignee: Affymax, Inc.Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
-
Publication number: 20110282029Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: December 10, 2010Publication date: November 17, 2011Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
-
Publication number: 20090048147Abstract: The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, ?, and ? are each integers whose values are independently selected. Alternatively, the linker structure may have the following structure: wherein ? and ? are each integers whose values are independently selected.Type: ApplicationFiled: January 30, 2008Publication date: February 19, 2009Applicant: Affymax, Inc.Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
-
Publication number: 20090005292Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: November 11, 2005Publication date: January 1, 2009Applicant: AFFYMAX, INC.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
-
Publication number: 20080108564Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.Type: ApplicationFiled: April 13, 2007Publication date: May 8, 2008Applicant: Affymax, Inc.Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower